전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved23 programs
AntibodyLimited DatastaleAsan Medical CenterPhase 2

nivolumab (Opdivo, Regorafenib/Nivolumab)

Carcinoma, Hepatocellular; Hepatoma · Carcinoma, Hepatocellular

#CarcinomaHepatocellular#Antibody#Phase2#monoclonal-antibody#Carcinoma+3
Trials 1Status Active
CGTLimited DatastaleShanghai GeneChem Co., Ltd.Phase 2

TAI-GPC3-CART cells (TAI-GPC3-CART cells)

Carcinoma, Hepatocellular · Carcinoma, Hepatocellular

#CarcinomaHepatocellular#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
ADCLimited DatastaleBoryung Pharmaceutical Co., LtdPhase 2

Trastzumab Deruxtecan (Trastzumab Deruxtecan)

Ovarian Cancer; Ovarian Carcinoma, Recurrent · Ovarian Cancer

#OvarianCancer#ADC#Phase2#antibody-drug-conjugate#OvarianCarcinoma+2
Trials 1Status Recruiting

2 / 2 pages

← PreviousNext →